AGT and cardiac hypertrophy: More importantly, this class II HDACs‐mediated inhibition of COX2/PGE2 pathway may be an possible mechanism by which NaBu fights against Ang II‐induced cardiac hypertrophy and may provide a new insight for novel therapeutic targets for cardiac hypertrophy treatment.